Disease Domain | Count |
---|---|
Infectious Diseases | 4 |
Endocrinology and Metabolic Disease | 1 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Prophylactic vaccine | 1 |
Vaccine | 1 |
Monoclonal antibody | 1 |
Antitoxin | 1 |
Target |
Mechanism Proton pump inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date03 Mar 1992 |
Target |
Mechanism DHPS inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date30 Jul 1973 |
Target |
Mechanism 30S subunit inhibitors |
Active Org. |
Originator Org.- |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date01 Jan 1966 |
Start Date02 Aug 2024 |
Sponsor / Collaborator |
Start Date01 May 2024 |
Sponsor / Collaborator Institut Pasteur [+2] |
Start Date15 Apr 2024 |
Sponsor / Collaborator Institut Pasteur [+3] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
AMT-110 ( NAGLU ) | Mucopolysaccharidosis III More | Phase 2 Clinical |
SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine | Dysentery, Bacillary More | Phase 2 |
MAG-TN3 + AS15 vaccine | Breast Cancer More | Phase 1 |
Disodium edetate/Gentamicin Sulfate ( 30S subunit ) | Infectious Diseases More | Phase 1 |
Gentamicin Sulfate ( 30S subunit ) | Infectious Diseases More | Phase 1 |